Quantcast

Industry news that matters to you.  Learn more

Bruker Announces Powerful New Mass Spectrometry Systems and Solutions for Life-Science Research, Clinical Research, Biopharma and Applied Markets

At the 62nd ASMS Conference on Mass Spectrometry and Allied Topics recently, Bruker Corporation (NASDAQ:BRKR) announced mass spectrometry-based product introductions for life-science research and proteomics, for clinical research, for pharma/biopharma/CRO customers, as well as for applied and industrial markets. The new systems and solutions are designed to deliver confident analyses with significantly enhanced performance, productivity and versatility.

The Ongoing Collaboration Aims to Exploit the High Throughput, Robustness and Ease of Use of MALDI-TOF Instruments

At the 12th HUPO World Congress, Bruker Corporation (NASDAQ: BRKR) recently announced the start of a second-phase collaboration agreement with SISCAPA Assays Technologies, Inc. (SAT). The ongoing collaboration aims to exploit the high throughput, robustness and ease of use of MALDI-TOF instruments as an alternative to nano-LC-MS technology currently used in many SISCAPA assays.

Bruker and SISCAPA Assay Technologies Announce Joint Publication on SISCAPA-MALDI-TOF Mass Spectrometry for Biomarker Validation and Clinical Research

Bruker Corporation and SISCAPA Assay Technologies, Inc. (SAT) today announced the publication of a study in the Journal of Proteome Research demonstrating that SISCAPA MALDI-TOF mass spectrometry provides excellent precision for quantitation of proteins of interest, such as high value protein biomarkers. The publication results from an ongoing collaboration between Bruker and SAT to develop MALDI-TOF as a high precision and high throughput mass spectrometric detection method for SISCAPA (Stable Isotope Standards and Capture by Anti-Peptide Antibodies) assays.